What is the recommended first‑line pharmacologic treatment for anxiety in an adult, including dosing, titration, alternative agents, and short‑term adjuncts?

First-Line Pharmacologic Treatment for Adult Anxiety

Escitalopram (10–20 mg/day) or sertraline (50–200 mg/day) are the recommended first-line medications for adult anxiety disorders, with gradual titration over 1–2 weeks to minimize early activation symptoms and a full 12-week trial required before declaring treatment failure. 1, 2

---

Initial Medication Selection and Dosing

Preferred First-Line SSRIs

• Escitalopram should be started at 5–10 mg daily and increased by 5–10 mg increments every 1–2 weeks to a target dose of 10–20 mg/day. 1, 2, 3
• Sertraline should be initiated at 25–50 mg daily and titrated by 25–50 mg increments every 1–2 weeks to a target dose of 50–200 mg/day. 1, 2, 4
• These two agents are prioritized because they have the lowest drug-interaction potential, minimal discontinuation symptoms, and favorable side-effect profiles compared with other SSRIs. 1, 2

Rationale for Gradual Titration

• Starting at lower doses and advancing slowly reduces the risk of early-treatment anxiety, agitation, or activation that can occur when SSRIs are initiated. 1, 2
• Dose changes should not occur at intervals shorter than 1 week to allow adequate assessment of tolerability and avoid overshooting the therapeutic window. 1

---

Expected Timeline for Therapeutic Response

• Week 2: Statistically significant symptom improvement may begin to emerge. 1, 2
• Week 6: Clinically meaningful improvement is typically evident. 1, 2
• Week 12 or later: Maximal therapeutic benefit is generally achieved; do not discontinue prematurely, as full response often requires ≥12 weeks of continuous therapy. 1, 2

---

Second-Tier SSRI Options

• Paroxetine (20–60 mg/day) and fluvoxamine are equally effective but reserved for second-line use because they carry higher rates of discontinuation symptoms and greater potential for drug-drug interactions. 1, 2

---

Alternative First-Line: SNRIs

Venlafaxine Extended-Release

• Venlafaxine XR (75–225 mg/day) is an effective alternative when an SSRI is ineffective after an adequate 8–12 week trial at therapeutic doses. 1, 2, 5
• Blood-pressure monitoring is required because venlafaxine can cause sustained hypertension. 1, 2

Duloxetine

• Duloxetine (60–120 mg/day) demonstrates efficacy for generalized anxiety disorder and provides additional benefit for patients with comorbid pain conditions. 1

---

Short-Term Adjuncts (Benzodiazepines)

• Benzodiazepines (e.g., alprazolam, clonazepam) should be limited to short-term adjunctive use (days to a few weeks) only because of high risks of dependence, tolerance, cognitive impairment, and withdrawal syndromes. 1, 2, 5
• They are not recommended as first-line or long-term therapy for anxiety disorders. 1, 2
• Reserve benzodiazepines for severe acute symptomatic distress while awaiting SSRI/SNRI onset of action, then taper and discontinue within 2–4 weeks. 1

---

Strategy for Inadequate Response (After 8–12 Weeks at Therapeutic Dose)

1. Switch to a different SSRI (e.g., from sertraline to escitalopram or vice versa) if response remains inadequate despite good adherence. 1, 2
2. Add individual cognitive-behavioral therapy (CBT) if it has not yet been implemented; combined treatment yields superior outcomes compared with medication alone. 1, 2
3. Consider an SNRI (venlafaxine or duloxetine) as a second-line pharmacologic option. 1, 2

---

Essential Psychotherapy Component

• Individual cognitive-behavioral therapy (12–20 sessions) has the highest level of evidence for anxiety disorders, with large effect sizes (Hedges g ≈ 1.0 for generalized anxiety). 1, 2
• Individual CBT is preferred over group CBT because it yields superior clinical outcomes and is more cost-effective. 1, 2
• Core CBT components include psychoeducation about anxiety, cognitive restructuring of distorted thoughts, relaxation techniques, and graded exposure when appropriate. 1, 2
• For moderate-to-severe anxiety, combining an SSRI with individual CBT produces greater symptom reduction and functional improvement than either modality alone (moderate-to-high strength of evidence). 1, 2

---

Common SSRI/SNRI Adverse Effects and Monitoring

• Typical side effects include nausea, sexual dysfunction, headache, insomnia, dry mouth, diarrhea, heartburn, sedation, dizziness, and vivid dreams. 1, 2
• Most adverse effects appear within the first few weeks and usually resolve with continued treatment. 1, 2
• All SSRIs carry a boxed warning for suicidal ideation and behavior; close monitoring is essential during the first months of treatment and after dose adjustments, with pooled absolute rates of ≈1% versus 0.2% for placebo. 1, 2

---

Duration of Treatment and Relapse Prevention

• Continue effective medication for at least 9–12 months after achieving remission to reduce relapse risk. 1, 2
• Monitor symptoms monthly until stability is achieved, then every 3 months thereafter. 1
• Taper the medication gradually over 10–14 days (or longer) when discontinuing to avoid withdrawal symptoms, especially with short-half-life SSRIs. 1, 2, 3

---

Medications to Avoid

• Beta-blockers (atenolol, propranolol) are not recommended for generalized anxiety disorder or social anxiety disorder according to Canadian guidelines due to negative evidence. 1, 2
• Tricyclic antidepressants should be avoided due to unfavorable risk-benefit profiles, particularly cardiac toxicity. 1

---

Adjunctive Non-Pharmacologic Interventions

• Structured physical activity and exercise produce moderate to large reductions in anxiety symptoms. 1, 2
• Breathing exercises, progressive muscle relaxation, grounding techniques, and mindfulness are useful adjuncts to primary treatment. 1, 2
• Avoid excessive caffeine and alcohol, as both can exacerbate anxiety symptoms. 1

---

Critical Clinical Pitfalls to Avoid

• Do not initiate pharmacotherapy for mild anxiety (GAD-7 score 5–9) before trying evidence-based non-pharmacologic options such as CBT, which provide more durable benefits. 1, 2
• Do not interpret lack of early improvement as treatment failure; a full response often requires ≥12 weeks of continuous therapy. 1, 2
• Approximately 50% of patients do not achieve complete remission with first-line pharmacotherapy alone, underscoring the need for adjunctive strategies such as CBT. 2
• Allow 1–2 weeks between dose increases to assess tolerability and stay within the therapeutic window; avoid rapid escalation. 1